USPTO serial 79402456
EXOPULSE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 4, 2026
- Examiner
- THOMAS, JULIE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with EXOPULSE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Clifford D. Hyra
Clifford D. Hyra Fresh IP PLC11710 Plaza America Drive Suite 2000Reston, VA 20190United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Extracellular vesicles, namely, exosomes for medical use; extracellular vesicles for clinical use; biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications; living cells for medical purposes; pharmaceutical preparations and substances, namely, extracellular vesicles for treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, respiratory diseases, immunoregulatory disorders, metabolic disorders, infectious disorders, reproductive disorders, skin disorders, and hair loss disorders; dermatological preparations; pharmaceutical preparations for the treatment of cells; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified extracellular vesicles for therapeutic use; pharmaceutical preparations, namely, extracellular vesicles to deliver protein or RNA for genetic therapy; biological preparations for use in cell cultures for medical purposes; biological preparations comprising extracellular vesicles for medical purposes; biological preparations comprising a therapeutic target protein-loaded extracellular vesicles for medical purposes; biological preparations comprising extracellular vesicles for pharmaceutical purposes; biological reagents for medical use; medical preparations for treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, respiratory diseases, immunoregulatory disorders, metabolic disorders, infectious disorders, reproductive disorders, skin disorders, and hair loss disorders; none of the aforesaid products being for use in relation to ultrasound-based medical, diagnostic or therapeutic imaging apparatus or devices used for medical, diagnostic or therapeutic imaging and related software | ACTIVE | — |
| 040 | Custom manufacturing of pharmaceutical preparations and substances, cosmetics, dermatological preparations, biological preparations comprising extracellular vesicles, such as exosomes for therapeutic applications for others; custom manufacturing consultancy with regard to aforementioned services; none of the aforesaid services being for use in relation to ultrasound-based medical, diagnostic or therapeutic imaging apparatus or devices used for medical, diagnostic or therapeutic imaging and related software | ACTIVE | — |
| 042 | Contract new product research and contract new product development in the field of pharmaceutical preparations and substances, cosmetics, dermatological preparations, biological preparations comprising extracellular vesicles, such as exosomes for therapeutic applications; biotechnological and medical research and product development; extracellular vesicles research and development for therapies; culturing of cells and tissues for others for scientific research purposes; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services in the field of extracellular vesicles; biological research; clinical research in the field of extracellular vesicles; providing medical and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; scientific research in the nature of conducting clinical trials for others; scientific consultancy with regard to aforementioned services; none of the aforesaid services being for use in relation to ultrasound-based medical, diagnostic or therapeutic imaging apparatus or devices used for medical, diagnostic or therapeutic imaging and related software | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EXO Biologics, Société anonyme
- Other trademarks owned by EXO Biologics, Société anonyme
- Other trademarks owned by EXO Biologics, Société anonyme
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named EXOPULSE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 4, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 30, 2026 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jun 16, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 16, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 10, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 19, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 24, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 24, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 24, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 24, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 24, 2025 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Oct 8, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 8, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 8, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 9, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 9, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 9, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 10, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 10, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 19, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 18, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 25, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 23, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 23, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 15, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |